Format

Send to

Choose Destination
Am J Ophthalmol. 2018 May;189:122-126. doi: 10.1016/j.ajo.2018.03.005. Epub 2018 Mar 9.

Correlation of Immunocytochemistry of BRCA1-associated Protein-1 (BAP1) With Other Prognostic Markers in Uveal Melanoma.

Author information

1
Department of Ophthalmology, Stein Eye Institute, UCLA School of Medicine, Los Angeles, California; Department of Pathology and Laboratory Medicine, Stein Eye Institute, UCLA School of Medicine, Los Angeles, California. Electronic address: bglasgow@mednet.ucla.edu.
2
Department of Ophthalmology, Stein Eye Institute, UCLA School of Medicine, Los Angeles, California.

Abstract

PURPOSE:

Prior studies have shown that nuclear reactivity for BRCA1-associated protein-1 (BAP1) yields prognostic information for paraffin-embedded uveal melanomas. Lacking are immunocytochemical studies of BAP1 on fine needle aspiration biopsies of uveal melanoma that correlate with prognosis or other markers of prognosis. Our purpose was to fill this gap.

DESIGN:

Experimental laboratory study.

METHODS:

Fine needle aspiration biopsies were performed prospectively on 113 patients with uveal melanomas, garnering limited subsets of cases for comparison. Agreement between immunocytochemistry for BAP1 nuclear staining vs chromosome 3 ploidy analysis and gene expression profiling was assessed by 2 × 2 contingency table analysis.

RESULTS:

The presence or absence of suppression of nuclear expression of BAP1 was strongly associated (73%, P = .000002) with monosomy and disomy chromosome 3, respectively. BAP1 nuclear expression was also correlated with gene expression profiling. Chromosome 3 ploidy analysis correlated with gene expression profiles.

CONCLUSION:

When adequate material is obtained, immunocytology using BAP1 is a potentially informative tool for prognostication of uveal melanoma.

PMID:
29530782
PMCID:
PMC5915968
DOI:
10.1016/j.ajo.2018.03.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center